Epigenetic reversal of field cancerization
EpiKare Bio is a Swiss biotechnology company developing first-in-class nuclear kinase inhibitors to address the epithelial and stromal changes underlying field cancerization.
Our therapeutic approach
Selective nuclear kinase inhibition
Novel, highly selective inhibitors targeting nuclear kinases and associated molecules involved in the changes underlying field cancerization.
Epigenetic reprogramming and reversal
An approach designed to reset altered epithelial and stromal cell states and reverse field cancerization, without inducing inflammation.
Topical development
Developing topical therapies with the goal of improving tolerability and enabling long-term disease control.
Understanding field cancerization
- Chronic sun exposure and smoking can induce skin aging, affecting both the epidermis and the underlying dermis. This results in cancer-prone fields, which can give rise to multiple, recurrent precancerous and cancerous lesions.
- Actinic keratoses are visible manifestations of this field damage and represent EpiKare’s initial therapeutic focus.
- Many current field therapies act through tissue-destructive or inflammatory mechanisms.
Advancing a new therapeutic approach
- Our lead compounds have shown activity in cellular, 3D tissue and preclinical models, supporting further development of nuclear kinase inhibition for cutaneous field cancerization.
- We are advancing lead optimization and preclinical evaluation toward the selection of a topical development candidate.
- Our long-term goal is to develop well-tolerated therapies for treatment and prevention of cutaneous field cancerization.
Expertise behind EpiKare
Our team brings together expertise in epithelial and stromal biology, drug discovery and clinical dermatology to advance epigenetic therapies for cancer-prone fields.
Connect with EpiKare
We welcome enquiries from research collaborators, development partners and investors interested in advancing our therapeutic approach.